Phone: +31 61 358 5896
Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is a common neurological disease that is frequently unrecognized, misdiagnosed and poorly treated. Patients often describe it as being characterized by highly uncomfortable sensations deep in the legs, arms and sometimes other parts of the body, that occur in rest situations and cause an irresistible urge to move. Symptoms are particularly troublesome in the evening and night. Sleep disturbances are consequently very common.
WHAT IS RLS?
(Restless Legs Syndrome)
The International RLS Study Group (www.irlssg.org) have set out criteria on which a diagnosis of RLS may be made. These are:
RLS occurs in 7-10 % of the adult population worldwide. One third of these patients need pharmaceutical treatment to live a normal life.
There are two forms of RLS:
The exact cause of RLS is not known. Many recent studies have shown that there is impaired dopaminergic neurotransmission. There is no dopaminergic hypofunction. New data point towards a hyper dopaminergic neuronal extracellular situation. Iron plays an important role in the optimal function of the dopaminergic system.
RLS is often unrecognized or misdiagnosed. Patients usually delay seeking medical help for many years. When they finally do, an accurate diagnosis often is not made until many years thereafter. A large study completed in 2004 showed that only 8% of the many thousands of patients who took part received an RLS diagnosis.
Many people with RLS have relatively mild symptoms which may be alleviated by changes in lifestyle, such as avoiding alcohol and nicotine. But there is a substantial group of patients with symptoms so severe that treatment is called for. The chronic lack of sleep that accompanies RLS often significantly impacts on daytime functioning, and therefore quality of life.
RLS is an important disease because it is common, because it causes significant distress to the sufferers, because it may be the presenting symptom of another serious underlying disease.
Non-Pharmaceutical Therapy: There are now a number of proven and effective therapies for the treatment of RLS symptoms. However, the first issue for a doctor to decide is whether or not drug therapy is necessary. Non-drug treatment should first be considered in all but the most severe of cases. These include:
The potential impact of other drugs should also be taken into account. Many antidepressants, antihistamines, most antinausea agents and most antipsychotics have the potential to cause or increase RLS symptoms and should be avoided if possible.
Pharmaceutical Therapy: Dopamine agonists are now the treatment of first choice for primary or idiopathic RLS. Pramipexole, Ropinirole and Rotigotine have all been shown to be safe and effective in treatment of RLS and are also approved by EMEA (the European Medicines Agency). Studies have shown that these drugs are well tolerated. Augmentation and rebound may occur and tend to increase with increased dosage of dopamine agonists. As there is no dopamine deficiency, but possibly an extra neuronal hyper dopaminergic state, in RLS patients it is vital to start, and to continue, with a very low dose of dopaminergics - dopamine agonists and L-Dopa. Too high doses can quickly give side effects.
If dopamine agonists are poorly tolerated or ineffective, antiepileptics (Gabapentin and Pregabalin) or opioids (Oxycodone, Tilidin and Tramadol) may be considered.
Treatment of secondary or symptomatic RLS involves treating the underlying problem in the first instance. Iron deficiency is important for these RLS sufferers. Please contact your national RLS patient organization for further educational materials.